PGT-M and a Variant of Uncertain Significance: Why Genetic Counselling Comes First

Request the original report and note the exact variant classification, gene, transcript, condition and laboratory interpretation date. “Pathogenic,” “likely pathogenic” and “variant of uncertain significance” represent different levels of evidence. Classification can change as knowledge develops. Ask whether the laboratory has issued an updated interpretation and whether a specialist recognises the variant as relevant to your family. Do not assume that an online list of gene-associated diseases proves your finding causes the same condition.

A clinical geneticist may ask who has the condition, how it was diagnosed, whether relatives have similar findings and whether other genes could explain the medical story. Sometimes targeted testing in family members may help interpretation, but this should be offered only with appropriate consent and counselling. Where the finding is not clearly disease-causing, embryo selection could create decisions based on uncertain biological information. Patients deserve explicit discussion of what would and would not be learned.

PGT-M involves a tailored genetic testing strategy in an IVF laboratory and often requires preparation before embryo creation. Laboratories may need family reference samples or validated assay design. A report saying “genetic finding” does not guarantee that a usable targeted test can be developed. Ask about potential inconclusive results, the possibility of having no embryos suitable for transfer and the limitations of embryo biopsy. A genetic counsellor should explain relevant prenatal diagnostic options if pregnancy is achieved.

PGT-A evaluates chromosome copy-number patterns; PGT-M is designed for defined single-gene conditions. They have different purposes, limitations and indications. A VUS does not become a diagnosed monogenic condition because PGT-A is added. ASRM has advised against routine PGT-A for every IVF patient. When uncertainty remains, the decision may involve revisiting genetic classification rather than starting a new IVF cycle immediately. Any proposed embryo-testing package needs a documented reason tied to the family’s findings.

Ask which consultations, report reinterpretation, assay development, embryo biopsy, cryopreservation and embryo transfer charges are included, and what happens if the lab cannot validate the test. Patients should understand what an uncertain result means for confidentiality and relatives before consenting to share genetic data. HomeIVF can coordinate consultation and records where available, but DNA analysis, embryo biopsy, culture and transfer require specialised facilities. A good service never replaces clinical genetic counselling with a sales checklist.

HomeIVF is a doctor-led fertility and IVF care-coordination approach intended to reduce unnecessary clinic visits while maintaining essential clinical oversight. In an appropriate case, some counselling may be provided by teleconsultation; selected prescribed blood collection, medication teaching or injection support may be considered only where trained personnel, laboratory handling, local serviceability and the treating clinician permit. A person is never promised services merely because a locality appears in search results. Ultrasound scans when required, IUI, egg retrieval, sperm-retrieval procedures, embryology, genetic embryo testing, egg and embryo storage, and embryo transfer take place at suitably equipped facilities. Convenience is part of care; it cannot replace medical safety.

Turn the decision into a simple responsibility map: which specialist interprets the finding, who signs any prescriptions, where ultrasound or clinical examination will occur and which laboratory handles specimens or embryos. Selected routine questions and record reviews may be managed remotely where appropriate, but clinical decisions require access to validated results and a clear escalation pathway. If a test is collected outside a facility, ask who receives it, whether the sample-handling rules are met and what happens if the report is delayed. A useful remote review should make the in-person appointment more focused, not encourage the patient to skip it.

For the next appointment, save reports as dated originals rather than cropped screenshots. Include medicine names and doses, any previous stimulation or IUI records, relevant scans, semen analysis where applicable, operative notes and the exact questions you hope to resolve. Keep a short timeline of symptoms and decisions. Ask the treating clinician which tests are still necessary and which can be reused. Where a second opinion is requested, a summary is helpful but it cannot replace access to the underlying reports. This can make a doctor-led consultation more productive without creating a new testing burden.

Before agreeing to a plan, request a dated, itemised estimate. Separate consultations, investigations, ultrasound, medicines, procedures, anaesthesia, laboratory services, storage and later transfers. Ask which items are optional and clinically justified, which are already included and what happens if the pathway changes or a procedure is not performed. Do not infer a price from someone else’s experience or a published package banner. A cost discussion should make room for follow-up, travel and uncertainty without inventing savings from home support or promising any result.

A treating clinician must give individual safety instructions. Severe or worsening abdominal pain, heavy bleeding, fainting, breathing difficulty or significant illness during fertility treatment or early pregnancy requires prompt medical assessment; urgent symptoms should not wait for a home visit or routine teleconsultation. Medicines and injection timing must not be changed based on a web article. If the clinical team requests an ultrasound or in-person examination, it remains necessary despite any opportunity for home support. This guide is educational and cannot diagnose or prescribe.

When a genetic finding is uncertain, the ethical first step is to clarify its meaning—not to promise that more laboratory testing will remove uncertainty.

The purpose of care coordination is to make appointments purposeful while preserving all clinical and laboratory safeguards.